Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 2/20 | 0.67 |
| ▸ | RET | P07949 | 8/20 | 0.53 |
| ▸ | KIF5B | P33176 | 8/20 | 0.53 |
| ▸ | KDR | P35968 | 7/20 | 0.53 |
| ▸ | ETV6 | P41212 | 5/20 | 0.53 |
| ▸ | CCDC6 | Q16204 | 4/20 | 0.51 |
| ▸ | LCK | P06239 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 3/20 | 0.50 |
| ▸ | LYN | P07948 | 3/20 | 0.50 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.50 |
| ▸ | FGR | P09769 | 3/20 | 0.50 |
| ▸ | KIT | P10721 | 3/20 | 0.50 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.50 |
| ▸ | BLK | P51451 | 3/20 | 0.50 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | NPM1 | P06748 | 2/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4695093 | 0.92 | FYN (0.68) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4179850 | 0.87 | FYN (0.71) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4695452 | 0.85 | FYN (0.60) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4167662 | 0.85 | FYN (0.59) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4175269 | 0.84 | MEN1 (0.50) | FYNMAPTMEN1KMT2ANPC1 | |
| SCHEMBL14310653 | 0.84 | MEN1 (0.50) | FYNKDRMAPTMEN1KMT2A | |
| SCHEMBL18613401 | 0.80 | FYN (1.00) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL30521695 | 0.80 | FYN (1.00) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4178858 | 0.79 | FYN (0.57) | FYNRETKIF5BKDRETV6 | |
| SCHEMBL4692302 | 0.79 | KMT2A (0.55) | FYNRETKIF5BKDRETV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | claimed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | claimed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | claimed |
| US-20090099167-A1 | Organic compounds | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH | 2009-04-16 | — | — | US | disclosed |
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | SIVASANKARAN RAJEEV | 2009-03-12 | — | — | US | disclosed |
| EP-1993552-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | Novartis AG (CH) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007103432-A9 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007103432-A2 | USE OF PYRAZOLO[1,5A]PYRIMIDIN-7-YL AMINE DERIVATIVES IN THE TREATMENT OF NEUROLOGICAL DISORDERS | NOVARTIS AG (CH) | 2007-09-13 | — | — | WO | disclosed |
| EP-1708710-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | Novartis AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20050222171-A1 | Organic compounds | NOVARTIS AG (CH) | 2005-10-06 | — | — | US | disclosed |
| WO-2005070431-A1 | PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069315-A1 | Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders | EPHA5, EPHA7, EPHA1 | FYN 360/4885RET 252/4885KIF5B 1372/4885 |
| US-20050222171-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | FYN 217/4885RET 166/4885KIF5B 1833/4885 |
| US-20090099167-A1 | Organic compounds | JAK1, MAP3K5, MAP3K7 | FYN 217/4885RET 166/4885KIF5B 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.